クリングルファーマ株式会社.

NEWS

お知らせ


Warning: Invalid argument supplied for foreach() in /home/r3716923/public_html/kringle-pharma.com/wp-content/themes/kringle_pharma/view/single/default.php on line 21
2019.01.07

ALS Phase I results published

Clinical data from Phase I study of recombinant human HGF, KP-100IT, for the treatment of ALS were published in Journal of Clinical Pharmacology (11 DEC 2018, DOI: 10.1002/jcph.1355). It was indicated that intrathecal administration of KP-100IT was safe and tolerable. Following the Phase I study, an investigator-initiated Phase II study is currently underway to confirm therapeutic efficacy of KP-100IT against ALS.